Latest

The launch of a new mRNA biotech spinout signals a structural shift in how next-generation RNA therapeutics are developed and commercialized.

Today’s podcast covers Phase II trispecific antibody data and evolving ADC strategies, which highlight durable, patient-centric approaches reshaping next-generation oncology therapy pipelines.

In a Phase II trial, Pfizer’s tilrekimig demonstrated well-tolerated, dose-dependent improvements in chronic Th2 inflammation, supporting further clinical development in atopic dermatitis.

Phase III trial results show that trastuzumab deruxtecan reduced invasive recurrence or death 53% in patients with residual HER2-positive disease after neoadjuvant therapy.

China’s approval of Sciwind’s ecnoglutide for weight management, alongside the company’s Pfizer commercialization deal, intensifies competition in the global GLP-1 market.

In today’s podcast, integrated biomarker modeling and dual-pathway immune checkpoint modulation highlight evolving strategies to improve translational efficiency and durability in oncology trials.

Updated analysis from the COMPASSION-03 Phase II trial links response depth to survival, which supports PD-1/CTLA-4 bispecific checkpoint strategies in heavily pretreated cervical cancer.

Advanced data strategies and specialist biometrics teams can deliver faster, cleaner insights from Phase I trials and power smarter early drug decisions, says Ben Edwards of Avance Clinical.

INOVIO and Akeso’s combination of DNA tumor antigen priming and dual checkpoint inhibition exemplifies adaptive trial strategies for challenging glioblastoma therapy.

Under the partnership, INOVIO and Akeso will evaluate DNA-encoded tumor antigen priming plus PD-1/CTLA-4 bispecific blockade in an adaptive Phase II trial for glioblastoma.

A newly engineered CHO host from Sartorius, developed through proteomic profiling and targeted genome editing, demonstrates up to three-fold productivity increases and accelerated nine-week cell line development timelines, supporting more stable, high-titer biomanufacturing for biologics and biosimilars.

Merck & Co. reported Phase III data showing that Keytruda plus Welireg significantly improved disease-free survival in high-risk clear cell renal cell carcinoma following surgery.

As the AI-first era matures, life sciences leaders must pivot from narrow, task-specific models toward integrated, interpretable frameworks that transform biological complexity into a sustainable competitive advantage.